Focus on GU Cancers: Current Clinical Experience With PD-1/PD-L1 Immune Checkpoint Inhibitors

Download this slideset from Scot Niglio, MD to see an overview of how IO biomarkers are currently used for patients with GU cancers, with key data on immunotherapy approaches for bladder cancer, RCC, and prostate cancer.
Scot Niglio, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.09 MB
Released: July 9, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL

Renier J. Brentjens, MD, PhD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

Frederick L. Locke, MD Released: December 3, 2020

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

Downloadable slides on current treatment landscape of patients with ovarian cancer from Clinical Care Options (CCO)

Bradley J. Monk, MD, FACS, FACOG Released: December 3, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue